Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. (Q37373486)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

review article

1 reference

title

Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

4

Darren K McGuire

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

author name string

Jason B Lindsey

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

Shuaib M Abdullah

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

language of work or name

English

0 references

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

Diabetes and Vascular Disease Research

20 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

20 January 2020

page(s)

7-14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19156622%20AND%20SRC:MED&resulttype=core&format=json

Preventing Type 2 diabetes and the dysmetabolic syndrome in the real world: a realistic view

20 January 2020

cites work

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Features of the metabolic syndrome predict higher risk of diabetes and impaired glucose tolerance: a prospective study in Mauritius

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Using metabolic syndrome traits for efficient detection of impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Components of the "metabolic syndrome" and incidence of type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Metabolic syndrome and development of diabetes mellitus: application and validation of recently suggested definitions of the metabolic syndrome in a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Prediction of incident diabetes mellitus in middle-aged adults: the Framingham Offspring Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The National Cholesterol Education Program - Adult Treatment Panel III, International Diabetes Federation, and World Health Organization definitions of the metabolic syndrome as predictors of incident cardiovascular disease and diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS).

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Association between inflammation and insulin resistance in U.S. nondiabetic adults: results from the Third National Health and Nutrition Examination Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

(How) can we prevent type 2 diabetes?

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Alpha-glucosidase inhibitors for type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Intensive Diabetes Treatment and Cardiovascular Disease in Patients with Type 1 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Diabetes mellitus and macrovascular disease: mechanisms and mediators

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Role of oxidative stress in development of complications in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Advanced protein glycosylation in diabetes and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Aminoguanidine prevents age-related arterial stiffening and cardiac hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Improved arterial compliance by a novel advanced glycation end-product crosslink breaker

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Advanced glycation end products stimulate an enhanced neutrophil respiratory burst mediated through the activation of cytosolic phospholipase A2 and generation of arachidonic Acid

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Diabetes-induced oxidative stress and low-grade inflammation in porcine coronary arteries

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Accumulation of Maillard reaction products in skin collagen in diabetes and aging

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Immunohistochemical colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions. Implication for glycoxidative stress in the pathogenesis of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

High serum levels of advanced glycation end products predict increased coronary heart disease mortality in nondiabetic women but not in nondiabetic men: a population-based 18-year follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Advanced glycation end products in nondiabetic patients with coronary artery disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Receptor for advanced glycation end products (AGEs) has a central role in vessel wall interactions and gene activation in response to circulating AGE proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

S100B-RAGE-mediated augmentation of angiotensin II-induced activation of JAK2 in vascular smooth muscle cells is dependent on PLD2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Understanding RAGE, the receptor for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Receptor for advanced glycation end products mediates inflammation and enhanced expression of tissue factor in vasculature of diabetic apolipoprotein E-null mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Vascular and inflammatory stresses mediate atherosclerosis via RAGE and its ligands in apoE-/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Receptor for advanced glycation end products (RAGE) deficiency attenuates the development of atherosclerosis in diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Neointimal hyperplasia after arterial injury is increased in a rat model of non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Increased restenosis in diabetes mellitus after coronary interventions is due to exaggerated intimal hyperplasia. A serial intravascular ultrasound study

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Receptor for AGE (RAGE) mediates neointimal formation in response to arterial injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Central role of RAGE-dependent neointimal expansion in arterial restenosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Receptor for advanced-glycation end products: key modulator of myocardial ischemic injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

RAGE modulates myocardial injury consequent to LAD infarction via impact on JNK and STAT signaling in a murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Peroxisome proliferator-activated receptor gamma down-regulates receptor for advanced glycation end products and inhibits smooth muscle cell proliferation in a diabetic and nondiabetic rat carotid artery injury model

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Thiazolidinediones reduce endothelial expression of receptors for advanced glycation end products

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

cDNA cloning of a novel secreted isoform of the human receptor for advanced glycation end products and characterization of cells co-expressing cell-surface scavenger receptors and Swedish mutant amyloid precursor protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

RAGE modulates vascular inflammation and atherosclerosis in a murine model of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002

Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.3132%2FDVDR.2009.002